Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.1342
- Book/Share 32.4693
- PB 4.73
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1201
- MktCap 369524230600.0
- FreeCF/Share 7.7211
- PFCF 19.8947
- PE 16.9397
- Debt/Assets 0.2698
- DivYield 0.0327
- ROE 0.2995
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Published: April 09, 2025 by: Benzinga
Sentiment: Positive
While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.
Read More
Pharma tariffs unlikely to hit earnings before 2026, analysts say
Published: April 09, 2025 by: Proactive Investors
Sentiment: Neutral
Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.
Read More
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Published: April 09, 2025 by: FXEmpire
Sentiment: Negative
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Read More
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ & PFE expect their sales and profits to improve in 2025.
Read More
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Published: April 02, 2025 by: Benzinga
Sentiment: Positive
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Why Johnson & Johnson Stock Is Sinking Today
Published: April 01, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.
Read More
Johnson & Johnson shares fall as US judge rejects $10B talc settlement plan
Published: April 01, 2025 by: Proactive Investors
Sentiment: Negative
Johnson & Johnson (NYSE:JNJ) shares moved almost 5% lower after a US bankruptcy judge rejected its $10 billion settlement proposal which sought to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston, dismissed the bankruptcy claim filed by J&J subsidiary Red River Talc, citing flaws in the voting process for personal injury claimants.
Read More
Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits
Published: April 01, 2025 by: New York Post
Sentiment: Negative
A judge rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its products caused ovarian cancer.
Read More
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
Published: April 01, 2025 by: Business Wire
Sentiment: Neutral
HOUSTON--(BUSINESS WIRE)--In a resounding victory for thousands of women who have suffered from ovarian cancer linked to Johnson & Johnson's (NYSE:JNJ) talcum powder products, U.S. Bankruptcy Court Judge Christopher Lopez has rejected the company's third attempt to shield itself from liability through bankruptcy. The ruling clears the way for claimants to seek speedy jury trials in state courts and through the bellwether process in multidistrict litigation (MDL). “This decision affirms what.
Read More
Why Johnson & Johnson (JNJ), United Health (UNH) And Procter & Gamble (PG) Are Holding the S&P 500 From Dropping More
Published: March 31, 2025 by: 24/7 Wall Street
Sentiment: Negative
As President Trump's April 2nd “Liberation Day” approaches, the stock market has been selling off due to uncertainties on the impact of the tariff policy implementation intended to even out the presently skewed international playing field.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
Read More
2 Recession-Proof Dividend Stocks to Buy and Hold
Published: March 27, 2025 by: The Motley Fool
Sentiment: Neutral
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.
Read More
Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets, aiming to generate sustainable dividend income and reduce portfolio volatility. Recent additions like Canadian Natural Resources and NextEra Energy enhance dividend growth potential and diversify sector allocation, reducing Financials Sector concentration. The portfolio boasts a Weighted Average Dividend Yield [FWD] of 3.98% and a 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.82%, ensuring attractive income and growth.
Read More
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or …
Read More
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.
Read More
J&J to Invest $55B in United States to Boost Manufacturing, R&D
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
Read More
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
Read More
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience RARITAN, N.J. , March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal …
Read More
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
Read More
Johnson & Johnson (JNJ) Could Be a Great Choice
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Mr. Joaquin Duato
- Employees 138100